Relebactam
Appearance
Clinical data | |
---|---|
Other names | MK-7655 |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C12H20N4O6S |
Molar mass | 348.37 g·mol−1 |
3D model (JSmol) | |
| |
|
Relebactam is a chemical compound used in combination with antibiotics to improve their efficacy. As a beta-lactamase inhibitor,[1] it blocks the ability of bacteria to break down a beta-lactam antibiotic. In the United States, relebactam is approved for use in the combination imipenem/cilastatin/relebactam (Recarbrio by Merck).[2]
See also
[edit]References
[edit]- ^ Papp-Wallace KM, Barnes MD, Alsop J, Taracila MA, Bethel CR, Becka SA, et al. (June 2018). "Relebactam Is a Potent Inhibitor of the KPC-2 β-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae". Antimicrobial Agents and Chemotherapy. 62 (6). doi:10.1128/AAC.00174-18. PMC 5971601. PMID 29610205.
- ^ "FDA approves new treatment for complicated urinary tract and complicated intra-abdominal infections". Food and Drug Administration. July 17, 2019.